Merkel cell carcinoma of the skin

BC Cancer Surgery Network Fall Update October 2019 Dr. Winkle Kwan, Radiation Oncologist

<u>Outline</u>


- What it is
- Clinical Features and Staging
- What to do with localized/nodal disease
 - Site of primary
 - Surgery surgical margins? How aggressive?
 - Radiotherapy After surgery? For gross disease?
 - Nodal drainage sites
 - Surgery sentinel node biopsy? Nodal dissection?
 - Radiotherapy Adjuvant with/without SNB? For gross disease
 - Treatment outcomes

What is Merkel cell CA?

- Small blue cell tumor of the skin
- Neuroectodermal origin from Merkel cell?
- Etiology
 - Sunlight (>90% patients of European origin)
 - Immunosuppression
 - Merkel cell polyomavirus
- ► Used to be rare, but 3x incidence 1986→2001

Diagnosis/Clinical Features

A	Asymptomatic
E	Expanding quickly (over 3 - 4 months)
I	Immunosuppressed individuals
0	Older (male > female)
U	UV exposed skin





Pathological DDX

Immunocytochemical differential diagnosis of Merkel cell carcinoma

Tumour	СК20	СК7	NSE	NFP	S100	LCA	CD99	TTF1
Merkel cell carcinoma	+	-	+	+	-	-	Rarely + (cytoplasmic)	_
Small cell carcinoma	-	+	+	+/-	-	-	Rarely + (cytoplasmic)	+
Lymphoma	-	-	-	-	-	+	-	-
Primitive neuroectodermal tumour	-	-	+	Rarely +	-	-	+ (membranous)	-
Small-cell melanoma	-	-	+	-	+	-	-	-

CK20: cytokeratin 20; CK7: cytokeratin 7; NSE: neuron-specific enolase; NFP: neurofilament protein; S100: S100 protein; LCA: leucocyte common antigen; CD99: cluster-of-differentiation antigen 99; TTF1: thyroid transcription factor 1; +: positive stain; -: negative stain.

UploDate

Reproduced with permission from: Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004; 5:593. Copyright© 2004 The Lancet.

Staging

- TNM and AJCC Stages I IV
- *Stage I*: Primary ≤ 2 cm, node negative
- Stage II: Primary > 2cm, node negative
- Stage III: Node positive
- Stage IV: distant metastases
- At presentation: Localized disease ~ 66%, Nodal disease ~ 25%, metastatic disease ~10%

Prognosis

- BC Cancer series* (1979 2007, N = 179) Median age 75, median tumor size 1.5cm
- MGH series** (1980 -2010, N = 161)
 Median age 72, median tumor size 2.3cm)

Cause specific Survival 5 yrs	Stage I	Stage II	Stage III
BC Cancer	88%	70%	64%
MGH	87%	63%	42%

* Harrington C: Ann Sug Oncol (2016) 23: 573-578 ** Santamaria-Barria JA: Ann Surg Oncol (2013) 20: 1365-1373

Management

>>> At the local disease site

Wide local excision

- How wide?
 - NCCN: 1 2 cm margins to investing fascia or pericranium when feasible
 - "... that any reconstruction involving extensive undermining ... be delayed until negative histologic margins are verified and SLNB is performed if indicated"
- Why do you need the 1 2 cm margin?
 - Early retrospective review suggested better overall survival*
 - Modern series with adjuvant radiation cast doubts on the need for wide excision
- BC Results:
 - If margin < 1 cm, No RT local recurrence 25% Vs 5% with RT
 - If margin > 1 cm, local recurrence 7% with/without RT

Wide excision not possible or cosmetically very undesirable ...

- Radiation likely can provide as good local control ...
- BC series*: 57 patients underwent primary radiotherapy in the presence of gross disease
 - 58% had clinical nodal disease (Stage III)
 - 5 year local relapse free = 90%
- Fred Hutchinson series**: 28 patients
 - All had nodal disease without nodal dissection
 - 2 year regional relapse free = 100% (microscopic disease) & 78% (palpable disease)

*Harrington C: Ann Surg Oncol (2014) 21: 3401-3405 **Fang LC: Cancer (2010) 116(7) : 1783-1790

Radiation alone for Merkel cell

- Australian systemic review
 - Outcomes of treatment with "definitive" radiotherapy
 - 332 sites of MCC radiated (Primary Vs regional ~50% each)
 - Findings:
 - In field control 75 85%
 - 5 year overall survival 40 60%

*Gunaratne DA: J Am Acad Dermatol (2017) 77 No. 1: 142-148

Summary slide: local disease

- Excise with 1cm margin minimum if possible
- If achieving the margin requires extensive disfiguring surgery, consider sending patient to oncologist
- Radiation to local site indicated if margin < 1cm</p>
- Definitive radiation to local site in the setting of gross disease results in good local control up to 90%

Management

>>> At the nodal drainage basin

Clinically node negative

BC results* (N = 137) nodal relapse rate

	Observation	Elective RT
Nodal relapse rate	23%	11%

Retrospective data exist showing patients given adj radiation have better OS .

- In the era of SLNB, we know why
 - MSKCC series**, 122 Stage I patients
 - SLNB yielded positive nodes in ~30%

In the absence of SLNB, we recommend adjuvant radiation to regional nodes

* Harrington C: Ann Sug Oncol 2016; 23: 573-578
 ** Gupta SG: Arch Dermatol 2006; 142: 685-690
 & Mojica P: J Clin Oncol 2007; 25:1043-1047
 & Bhatia S: J NCI 2016; 108(9) Epub 2016 May 31

Clinically N0 in the era of SLNB

Dana Farber series:

- If SLN -ve, no difference between control of those who received adjuvant therapy
- If SLN+, much better RFS if adjuvant therapy is given




Figure 3. Influence of adjuvant lymph node therapy on relapse-free survival in patients with a positive sentinel lymph node biopsy (SLNB) and those with a negative SLNB. A, Patients with a positive SLNB who did not receive adjuvant therapy had a 0% 3-year relapse-free survival rate vs 51% for those who received therapy (*P*<.01). Data are from 29 patients who had a positive SLNB and for whom follow-up was reported. B, Patients with a negative SLNB who did not receive adjuvant therapy had a 70% 3-year relapse-free survival rate vs 90% for those who received therapy (*P*=.26). Data are from 43 patients who had a negative SLNB and for whom follow-up was reported.

** Gupta SG: Arch Dermatol 2006; 142: 685-690

Summary slide Clinically Node Negative

- If no SLNB is done or if SLNB fails, adjuvant radiation is indicated
- If SLNB is negative, no adjuvant radiation
 If SLNB is positive, adjuvant radiation indicated

Clinically node positive

- NCCN guidelines:
 - Multidisciplinary tumor board or
 - Node dissection +/- radiation therapy or
 - Clinical Trial
- Depends on the bulk of disease
 - BC results (N = 42)

	Surgery alone (N=3)	Definitive RT (N=33)	Surgery + Adj RT (N=2)
Nodal relapse rate	33%	21%	33%

Clinically node positive Adjuvant chemotherapy?

No evidence it helps

- TROG 96-07 Phase II*
 - 40 patients treated with chemoRT (Etoposide & Platinum)
 - No improvement compared to historical patients (Queensland) treated without chemo
- MSKCC review, retrospective**
 - Patients who got adj chemo had poorer survival

*Poulson M: J Clin Oncol 2003; 21: 4371-4376 **Allen PJ: J Clin Oncol 2005; 23: 2300-2309



Friedrich Sigmund Merkel 1845 - 1919 German anatomist, pathologist